When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Primary sclerosing cholangitis

Last reviewed: 22 Sep 2024
Last updated: 14 Jul 2023

Summary

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • male sex
  • history of inflammatory bowel disease
Todos los datos

Otros factores de diagnóstico

  • age 25 to 45 years
  • abdominal pain
  • pruritus
  • fatigue
  • weight loss
  • fever
  • jaundice
  • steatorrhea
  • splenomegaly
  • ascites
  • encephalopathy
Todos los datos

Factores de riesgo

  • male sex
  • inflammatory bowel disease (IBD)
  • genetic predisposition
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • serum alkaline phosphatase
  • serum gamma-GT
  • serum aminotransferases (aspartate aminotransferase, alanine aminotransferase)
  • serum total bilirubin
  • serum albumin
  • CBC
  • prothrombin time
  • abdominal ultrasound
  • magnetic resonance cholangiopancreatography (MRCP)
  • serum IgG4
Todos los datos

Pruebas diagnósticas que deben considerarse

  • endoscopic retrograde cholangiopancreatography (ERCP)
  • serum immunoglobulins
  • 24 hour urine copper concentration
  • ceruloplasmin
  • antinuclear antibody
  • anti-smooth muscle antibody
  • antimitochondrial antibody
  • abdominal CT scan
  • liver biopsy
  • bone mineral density scan
  • colonoscopy
Todos los datos

Algoritmo de tratamiento

Agudo

early disease

end-stage liver disease

Colaboradores

Autores

S. Ian Gan, MD, FRCPC

Associate Clinical Professor

Vancouver General Hospital

University of British Columbia

Vancouver

BC

Divulgaciones

SIG declares that he has no competing interests.

Nawaf Tareq Aboalfaraj, MBBS, FRCPC

Gastroenterology Fellow

Vancouver General Hospital

University of British Columbia

Vancouver

BC

Divulgaciones

NTA declares that he has no competing interests.

Agradecimientos

Dr S. Ian Gan and Dr Nawaf Tareq Aboalfaraj would like to gratefully acknowledge Dr Kris V. Kowdley and Dr Christine Schlenker, the previous contributors to this topic.

Divulgaciones

KVK is a member of the speakers bureau of Axcan Pharma, manufacturer of Urso250 and Urso Forte, and gives one or two lectures a year on treatment of cholestatic liver diseases. KVK has also received funding from the NIH for a research study of Urso in PSC. CS declares that she has no competing interests.

Revisores por pares

Marlyn Mayo, MD

Associate Professor of Medicine

Division of Digestive and Liver Diseases

University of Texas Southwestern Medical Center

Dallas

TX

Divulgaciones

MM is an author of a reference cited in this topic.

James Neuberger, BM, BCh

Consultant Physician

Liver Unit

Queen Elizabeth Hospital

Birmingham

UK

Divulgaciones

JN declares that he has no competing interests.

  • Primary sclerosing cholangitis images
  • Diferenciales

    • Secondary sclerosing cholangitis
    • Immunoglobulin G4 cholangitis
    • Autoimmune hepatitis
    Más Diferenciales
  • Guías de práctica clínica

    • ACR Appropriateness Criteria: abnormal liver function tests
    • EASL clinical practice guidelines on sclerosing cholangitis
    Más Guías de práctica clínica
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad